Ajmera Realty launches a premium and mid-segment residential project; records 81% sell-out within 24 hours
MUMBAI, India, Dec. 11, 2025 /PRNewswire/ --Â In a recent development, Ajmera Realty…
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
– Company to host live webcast and conference call Monday, December 15,…
Mutuum Finance (MUTM) Completes Smart Contracts in Preparation for Q4 2025 Testing
Dubai, UAE, Dec. 14, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), a…
New Crypto Coin Mutuum Finance (MUTM) Nears 100% of Phase 6 Allocation as Investor Activity Accelerates
Dubai, UAE, Dec. 13, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM), a…
Milano Cortina 2026 organisers highlight Games readiness and momentum in update to the IOC Executive Board
10 December 2025 - As anticipation builds across Italy and beyond, the Milano…
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
Seizure reduction: phase 3 study achieved primary endpoint as fenfluramine demonstrated a…
Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition
December 06, 2025 17:30 ET Â | Source: TScan Therapeutics, Inc. Treatment arm…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…